Biocon Files PGR Petition Challenging Regeneron Eylea® Patent and Seeks Joinder with Alvotech Proceeding

On April 2, 2026, Biocon filed a petition for post-grant review (“PGR”) challenging Regeneron’s U.S. Patent No. 12,168,036 (“the ’036 patent”), which is directed to methods for treating angiogenic eye disorders using high doses of VEGF receptor fusion proteins.... By: Venable LLP